LDC000067
Cat. No.：YN270325
| 产品名称: | LDC000067 |
| CAS No.: | 1073485-20-7 |
| Chemical Name: | 3-[[6-(2-methoxyphenyl)-4-pyrimidinyl]amino]-benzenemethanesulfonamide |
| Synonyms: | LDC067 |
| 分子量: | 370.43 |
| 分子式: | C₁₈H₁₈N₄O₃S |
| SMILES: | O=S(CC1=CC=CC(NC2=NC=NC(C3=CC=CC=C3OC)=C2)=C1)(N)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | LDC000067是高度选择性的CDK9抑制剂，体外实验中IC50值为44±10 nM。 |
| IC50和靶点: | [{name:"CDK9- Cyclin T1:44 nM (IC50)"},{name: "cdk2-cyclin A:2441 nM (IC50)"},{name: "cdk1-cyclin B1:5513 nM (IC50)"},{name: "cdk4-cyclin D1:9242 nM (IC50)"},{name: "GSK3A:1460 nM (IC50)"},{name: "HGK/MAP4K4:820 nM (IC50)"},{name: "ABL2/ARG:3640 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Albert, T.K., Rigault, C., Eickhoff, J., et al.Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitorBr. J. Pharmacol.171(1),55-68(2014)
Xue, S., Zhu, L., Wang, C., et al.CDK9 attenuation exerts protective effects on catabolism and hypertrophy in chondrocytes and ameliorates osteoarthritis developmentBiochem. Biophys. Res. Commun.517(1),132-139(2019)
Xue, S., Shao, Q., Zhu, L.-B., et al.LDC000067 suppresses RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced osteolysis in vivoInt. Immunopharmacol.75:105826,(2019)
